Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 – Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering,… Read More
Drug development 2.0 – The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling… Read More
Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules… Read More
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace… Read More
Getting a handle on liquids: automation solutions for drug discovery By Helen Stewart-Miller and Thomas Hope The accurate and precise measurement of liquids and the transport of exact volumes between vessels, or from one instrument to another, are processes that constitute the very essence of research. Read More
Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These… Read More
By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might… Read More
Evolution of User Experience for life sciences By Jacek Ziemski, Simon Fortenbacher, James Hoeksma, Jan Taubert, Roger Attrill, Paula de Matos, Andre Richter and Julie Morrison Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an… Read More
Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In… Read More
Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal… driving stronger biomarker-based… Read More
Reducing the PAINS in High Throughput Screening: Assay design as a tool for maximising efficiency By Dr Philip S. Jones and Dr Stuart P. McElroy While the quality of the compound collection is frequently described as a key determinant of the success of a high throughput screening… Read More
How Artificial Intelligence is Transforming Drug Design By Dr Mark Roberts and Dr Sam Genway AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are… Read More
By Dr Alexander C. Maue It has become quite evident that the microbiome has the potential to impact drug discovery in vital ways. In addition to impacting study reproducibility and variability, the microbiome may influence drug efficacy or serve as a therapeutic agent. To… Read More
Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is… Read More
Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic By Dr Sue Grepper, Dr Radina Kostadinova, Dr Eva Thoma and Professor Armin Wolf Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. Read More
2030 Life Sciences and Health in the Digital Age (Part 1) By Dr Steve Arlington and John Wise One of the key ways in which The Pistoia Alliance works with its members is to help them not just deal with the problems of today, but also to… Read More